The influence of the vagal nerve on the inhibitory effect of neurotensin on pentagastrin stimulated gastric acid secretion was investigated in seven duodenal ulcer patients before and after parietal cell vagotomy without drainage. Preoperatively, neurotensin inhibited gastric acid secretion, whereas no effect was found postoperatively. Plasma concentration of neurotensin was identical pre-and postoperatively. This study shows that the inhibitory effect of neurotensin on gastric acid secretion is dependent on an intact vagal innervation of the parietal cell area.
In the gastrointestinal tract the tridecapeptide neurotensin has been found in peripheral nerves as well as in endocrine cells of the ileal mucosa.' 2 The peptide may act as an enterogastrone, because intraduodenal and intrajejunal instillation of fat inhibited gastric acid secretion and increased plasma concentration of neurotensin.3 4 In addition, intravenous infusion of neurotensin inhibited both pentagastrin stimulated and meal induced gastric acid secretion in healthy subjects.5 6 In duodenal ulcer patients intraduodenal fat inhibited gastric acid secretion and increased plasma concentrations of neurotensin but to a lesser degree than in a group of healthy subjects.3 When the patients were subjected to parietal cell vagotomy intraduodenal fat did not inhibit gastric acid secretion postoperatively.7 This suggests that the acid inhibitory effect of neurotensin depends on the vagal innervation of the parieial cell area. This possibility was tested in this study which reports the effect of intravenous infusion of exogenous neurotensin on gastric acid secretion in duodenal ulcer patients before and after parietal cell vagotomy.
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Results
During infusion of pentagastrin a significant increase in gastric acid secretion was found pre-as well as postoperatively (Fig. 1, Table) . Infusion of peurotensin, 500 ng/kg/h, decreased pentagastrinstimulated acid secretion preoperatively from a median acid output of 23 mmol H+/30 min (19.9-49.9) to 11-4 mmol H+/30 min (8-5-18-7) (p<0.01). Postoperatively neurotensin had no effect on gastric acid secretion (Fig. 1, Table) .
Plasma neurotensin concentrations were identical pre-and postoperatively in the control periods (60-90 minutes) as well as during infusion of neurotensin (150-180 minutes) respectively (Fig. 2) .
Duodenogastric reflux occurred in two samples that were excluded from the study. The coefficient of variation of repeated measures in the steady state was between 8 and 10%. Recovery of gastric acid has previously been determined using the present experimental design and was found to be approximately 90%. 
Discussion
Several studies have confirmed that exogenous neurotensin inhibits gastric acid secretion in healthy subjects.5 6 The effect on acid secretion in duodenal ulcer patients, however, has not been investigated.
This study shows that neurotensin inhibits gastric acid secretion in unoperated duodenal ulcer patients to the same extent as previously observed in healthy subjects.6 The study also suggests that it is unlikely that the increased acid secretion observed in a large proportion of duodenal ulcer patients12 is caused by an impaired inhibitory effect of neurotensin on gastric acid secretion.
The plasma concentrations of neurotensin obtained in this study are slightly above postprandial levels measured with this assay in normal subjects (25-100 pmol/l), but may still be considered to be within a physiological range.
After parietal cell vagotomy the inhibitory effect of neurotensin on acid secretion was abolished although the plasma concentrations of neurotensin were identical in the pre-and postoperative state. The degree of inhibition of stimulated acid secretion might depend on the pre-existing secretory rate. If, however, the pre-existing secretory rate is 50% of maximum or less as in this study, it is unlikely that the lack of inhibition by neurotensin postoperatively is dependant on the secretory rate.'
The mechanism of action of neurotensin on gastric acid secretion is unknown. The present results are in accordance with observations in dogs where neurotensin inhibited acid secretion by about 60% in the intact animal, whereas vagal denervation completely eliminated the inhibitory effect of neurotensin. 14 Neurotensin does not influence histamine stimulated gastric acid secretion15 and the present data that parietal cell vagotomy abolish the inhibitory effect of neurotensin suggest that the peptide does not act directly on the parietal cell. The demonstration of neurotensin containing nerves in the stomach16 fits with the hypothesis that neurotensin might act at a presynaptic level, but a decreased sensitivity to neurotensin after parietal cell vagotomy cannot be excluded.
Exogenous pancreatic glucagon inhibits meal and gastrin stimulated gastric acid secretion in healthy subjects and duodenal ulcer patients17 but does not inhibit histamine stimulated gastric acid secretion.18
Like neurotensin the acid inhibitory effect of glucagon is abolished in duodenal ulcer patients after parietal cell vagotomy.19 These observations suggest that intact vagal innervation of the parietal cell area is a condition for the function of both these acid inhibitory peptides. Neurotensin, however, might function more as a neurotransmitter than a hormone but this hypothesis needs to be verified by further studies. 
